FINWIRES · TerminalLIVE
FINWIRES

Xometry's Q2 Results Likely to Reflect Strength in Customer Growth, Revenue, Wedbush Says

By

Xometry's (XMTR) Q2 results will likely reflect strength in client growth, revenue and gross margins driven by product developments and strategic collaborations, Wedbush said in a note Thursday.

The company's agreement with Siemens, which involves a $50 million minority equity investment, is the most significant near-term catalyst for the company, according to the note.

Xometry is scheduled to report Q2 results on Aug. 4.

Product improvements driven by AI have led to sustained buyer growth and margin expansion. For Q2, the brokerage said it expects a Q2 revenue growth beat of 28.2%.

Xometry's product enhancements are showing up in unit economics, with marketplace margin expanding meaningfully in recent years as enterprise accounts scale rapidly, the analysts wrote.

Wedbush reiterated its outperform rating on the stock and price target of $126 per share.

Price: $84.18, Change: $+3.21, Percent Change: +3.96%

Related Articles

Wire

Houlihan Lokey Fiscal Q1 Adjusted Earnings, Revenue Fall; Shares Drop After Hours

Houlihan Lokey (HLI) reported fiscal Q1 adjusted earnings late Wednesday of $1.35 per diluted share, down from $2.14 a year earlier.Analysts polled by FactSet expected $1.64.Revenue in the three months ended June 30 fell to $511 million from $605 million a year earlier.Analysts expected $602.4 million.Houlihan Lokey shares fell 6.6% in after-hours trading.

$HLI
Wire

Four Corners Property Trust Q2 AFFO, Revenue Rise

Four Corners Property Trust (FCPT) reported Q2 adjusted funds from operations late Wednesday of $0.45 per diluted share, up from $0.44 a year earlier.Analysts polled by FactSet expected $0.45.Revenue in the quarter ended June 30 rose to $78.4 million from $72.8 million a year earlier.Four analysts expected $79 million.The company's shares rose 2% in after-hours trading.

$FCPT
Wire

Corcept Therapeutics Q2 Earnings, Revenue Rise; Shares Jump After Hours

Corcept Therapeutics (CORT) reported Q2 earnings late Wednesday of $0.36 per diluted share, up from $0.29 a year earlier.Analysts polled by FactSet expected $0.02.Revenue for the three months ended June 30 rose to $256.1 million from $194.4 million a year earlier.Analysts expected $221.1 million.The company boosted full-year revenue guidance to $1.1 billion to $1.2 billion from the prior forecast of $950 million to $1.05 billion.Analysts project $999.5 million.Corcept shares jumped 18% in after-hours trading.

$CORT